Advanced hepatocellular carcinoma
Conditions
Interventions
Group 1:TACE combined with arotinib
Sponsors
Affiliated Tumor Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients aged 18 to 80 years with hepatocellular carcinoma have a pre-survival period of more than 12 weeks 2.Liver cancer lesions were consistent with BCLC stage B/C; 3.Child-pugh score of liver function =90 g/L (no blood transfusion within 14 days); b. ANC >=1.5x10^9 /L; c.PLT >= 80x10^9 /L; (2) Biochemical tests must meet the following criteria: a. TBIL 50 ml/min (Cockcroft-Gault formula). 6. Women of child-bearing age were willing to use appropriate methods of contraception during the trial and 8 weeks after the last administration of the trial drug If necessary, carry out early pregnancy examination before the test, and it should be negative; 7. Subjects volunteered to participate in this study, signing of informed consent, good complianceand, cooperate with the follow-up.
Exclusion criteria
Exclusion criteria: 1. Clinical evaluation of patients with contraindications to TACE surgery; 2. A patient who is preparing for a liver transplant; 3. Abnormal coagulation function(INR >1.5 or prothrombin time > ULN+4 S), have bleeding tendencies or are receiving thrombolytic or anticoagulant therapy; 4. Before enrolling, he was treated with targeted anti-angiogenic drugs such as Anlotinib; 5. The heart, lungs, kidneys, brain and other organs are seriously dysfunctional; 6. Peripheral blood white blood cells caused by chemotherapy drugs or other drugs 160 mmHg, Diastolic blood pressure > 100 mmHg). 13. Urine routine showed urinary protein >= ++ or confirmed 24-hour urine protein ration > 1.0g; 14. Pregnant or lactating women; 15. Mental illness, or a history of substance abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Overall survival;Adverse reactions; | — |
Countries
China
Contacts
Public ContactChang Zhao
Intervention Unit, Affiliated Tumor Hospital of Guangxi Medical University
Outcome results
None listed